Search

Search Constraints

You searched for: Author/Creator Salwender, Hans

Search Results

1. Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide. Issue 2 (28th January 2020)

2. Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects. Issue 10 (23rd August 2020)

3. Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials. (19th July 2019)

4. Cyclophosphamide‐based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE. (24th May 2017)

5. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Issue 6 (June 2021)

6. Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma. (28th August 2021)

7. Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma. Issue 2 (February 2015)

8. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. (27th June 2017)

9. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. (29th September 2017)

10. Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells. Issue 1 (December 2015)